Sanofi to purchase the Biopharma US settings for $ 9.5 billion

Written by Dominique Patton and Jerot de Clerek

PARIS (Reuters) -French Sanofi has agreed to purchase the US -based plans plans company for 9.5 billion dollars to enhance its rare immunodeficiency position, in the largest deal concluded by a European health care company so far this year, according to LSEG data.

Blueprint is a specialist in systemic cell treatments and rare blood disorder.

The two companies said on Monday that Sanofi will initially pay $ 129.00 per share, or about 9.1 billion dollars. BluePrint shares jumped by 27 % to $ 128.74 in pre -market trade. Sanofi’s share decreased about 1 %.

Sanofi has adapted the spending on research and development in recent years, which prompted the company to abandon its long -term goals two years ago, as it seeks to build on the success of drugs blogge for eczema and other conditions.

However, he suffered a setback last week after a experimental drug for patients with a lung condition, usually called “smoked lung”, failed in a late experience.

Paul Hudson, CEO of Sanofi, said that the acquisition of the plan “represents a strategic step forward in our rare and immunosuppressive conservatives. It strengthens our pipeline and accelerates our transformation into the world’s leading immunity company.”

The deal will add to the Sanofi wallet Ayvakit, also known as Ayvakyt, also known as Ayvakyt, in the United States and the European Union, and advanced and early immunity pipeline.

Ayvakit is the only drug approved for advanced systemic pepty cells and survival, and it is a rare blood disorder that occurs when the body makes simple abnormal cells – a type of white blood cells. It leads to an ongoing sensitivity response.

This acquisition also brings elenestinib, a drug of the next generation for systemic breast cells, as well as the Blu-808, a collection of a very oral oral wild type that has the ability to deal with a wide range of diseases in immunology.

JP Morgan analysts said in a note, noting that BluePrint expects Ayvakit to reach annual sales of about two billion dollars by 2030.

“We see the treatment appropriate to Sanovi in ​​a reasonable evaluation, which investors should see as positive over time,” they added.

This is the latest in a series of deals by Sanofi. Last month, it announced the purchase of $ 470 million for neuroscience Viegel, and in January 2024, a $ 2.2 billion deal for the American Biotechnology Inhibrx.

Hudson said that the deal had completed the recent acquisitions of Sanofi for other drugs in the early stage, adding that it still maintains a great ability to more deals.